Piermont Capital Management buys $3,927,010 stake in Anika Therapeutics Inc (ANIK)

Anika Therapeutics Inc (ANIK) : Piermont Capital Management scooped up 66,788 additional shares in Anika Therapeutics Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 80,488 shares of Anika Therapeutics Inc which is valued at $3,927,010.Anika Therapeutics Inc makes up approximately 0.95% of Piermont Capital Management’s portfolio.

Other Hedge Funds, Including , Marshall Wace Llp sold out all of its stake in ANIK during the most recent quarter. The investment firm sold 19,081 shares of ANIK which is valued $930,962.Blackrock Advisors boosted its stake in ANIK in the latest quarter, The investment management firm added 355 additional shares and now holds a total of 23,692 shares of Anika Therapeutics Inc which is valued at $1,155,933.Thompson Siegel Walmsley reduced its stake in ANIK by selling 162,265 shares or 21.27% in the most recent quarter. The Hedge Fund company now holds 600,531 shares of ANIK which is valued at $29,371,971. Anika Therapeutics Inc makes up approx 0.44% of Thompson Siegel Walmsley’s portfolio.California State Teachers Retirement System reduced its stake in ANIK by selling 1,461 shares or 4.71% in the most recent quarter. The Hedge Fund company now holds 29,554 shares of ANIK which is valued at $1,421,547.

Anika Therapeutics Inc closed down -0.37 points or -0.77% at $47.99 with 91,567 shares getting traded on Monday. Post opening the session at $48.08, the shares hit an intraday low of $47.88 and an intraday high of $48.41 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Anika Therapeutics Inc reported $0.57 EPS for the quarter, beating the analyst consensus estimate by $ 0.13 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $0.44. The company had revenue of $26.60 million for the quarter, compared to analysts expectations of $24.73 million. The company’s revenue was up 16.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.51 EPS.

Anika Therapeutics Inc. develops manufactures and commercializes therapeutic products for tissue protection healing and repair. The Company’s products are based on hyaluronic acid (HA) a naturally occurring biocompatible polymer found throughout the body. The Company’s wholly owned subsidiary Anika S.r.l. has about 20 products commercialized primarily in Europe. These products are also all made from HA based on two technologies: HYAFF which is a solid form of HA and ACP gel an autocross-linked polymer of HA. The Company’s technologies for modifying the HA molecule allow product properties to be tailored specifically to therapeutic use. The Company offers therapeutic products from these technologies in the areas of: Orthobiologics Dermal (Advanced wound care and Aesthetic dermatology) Surgical (Anti-adhesion and Ear nose and throat care (ENT)) Ophthalmic and Veterinary.

Leave a Reply

Anika Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Anika Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.